REG - Hemogenyx Pharma Plc - Placing to Raise £4,056,250

Hemogenyx PharmaceuticalsAnnouncement

26/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230126:nRSZ9478Na&default-theme=true

RNS Number : 9478N  Hemogenyx Pharmaceuticals PLC  26 January 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON
LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE,
PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK
LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN
ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN
THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH
INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS
SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

 

26 January 2023

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Placing to Raise £4,056,250

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has
successfully raised £4,056,250 (before expenses) through the allotment and
issue of 162,250,000 new ordinary shares at 2.5 pence per share (the
"Placing", "Placing Shares"). The Placing was conducted by Peterhouse Capital
Limited and SP Angel Corporate Finance LLP as joint placing agents for the
Company.

The net proceeds from the Placing will be used to facilitate progression of
the Company's HEMO-CAR-T product candidate into clinical trials and to enable
the Company to continue development of product candidates for the treatment of
viral infections based on its Chimeric Bait Receptor ("CBR") platform.

An application is being made to the London Stock Exchange Main Market and
admission of the Placing Shares to trading is expected on or around 2 February
2023 ("Admission"). The Placing Shares will rank pari passu with the
existing ordinary shares in the Company.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
1,141,999,321 ordinary shares. The Company does not hold any shares in
treasury. The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the Company, under the
Disclosure Guidance and Transparency Rules.

Dr Vladislav Sandler,  CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented: "Shareholders are aware of the Company's recent progress in the
development of HEMO-CAR-T and our CBR platform. I am pleased to announce this
placing, which will enable the Company to progress with these two key product
candidates. It is important that we move HEMO-CAR-T into the clinic as quickly
as possible and maintain and consolidate our lead in the area of combatting
existing and emerging viral infections using our CBR-based product
candidates."

 

For the purposes of UK MAR, the person responsible for arranging for the
release of this Announcement on behalf of the Company is Dr Vladislav Sandler,
Chief Executive Officer & Co-Founder.

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

 

The Company is a pre-clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease and to bring
the curative power of bone marrow transplantation to a greater number of
patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses as engines
for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEKZGZMKVKGFZG